Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
Posted by Leanne Kodsmann on
Human Complement Serum from Innovative Research was used in the following study:
Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo
Experimental Hematology & Oncology, October 2018
"... Complement-rich human serum (CRHS) was from Innovative Research (Novi, MI), was aliquoted, cryopreserved and thawed for immediate use. For CDC studies, cells were aliquoted at 4 × 105 per well, incubated in 10% complement-rich serum with daratumumab or isotype control at 1 µg/mL for 15 min at room temperature, then for 1 h at 37° C in 5% CO2, and then were washed, resuspended with 5 μg/mL propridium iodide ..."
Related products available from Innovative Research also include: